Kineta Appoints Keith Baker as Chief Financial Officer
Seattle, WA — (October 4, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the a ...
CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2022 | April 13, 2022
Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27 shape adaptive anti-tumor immunity
Thierry Guillaudeux, Phd, Chief Scientific Officer European Society for Medical Oncology (ESMO) Immuno-Oncology Congress | December 8-11, 2021
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 Seattle, WA -- (April 12, 2021) Kineta, Inc., a clinical stage biotechnology company focused ...
Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506
Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 First in-human clinical trials will evaluate the safety and pharmacokinetics of a first-in-class α9α10 nicotini ...